tetano
Editor, Senior Moderator
J Clin Oncol. 2009 May 20;27(15_suppl):e20575.
[h=1]Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients.[/h] Chadha MK[SUP]1[/SUP], Fakih MG[SUP]1[/SUP], Tian L[SUP]1[/SUP], Mashtare T[SUP]1[/SUP], Nesline M[SUP]1[/SUP], Davis W[SUP]1[/SUP], Silliman C[SUP]1[/SUP], Trump DL[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] e20575 Background: Increasing epidemiologic data suggest association of vitamin D deficiency with influenza epidemic. Vitamin D acts as an immune modulator and stimulates the expression of protective anti-microbial peptides. We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to flu vaccine in cancer patients.
[h=4]METHODS:[/h] Cancer patients at Roswell Park Cancer Institute were offered trivalent (H1N1, H3N2, B/Malaysia) Flu vaccine (Fluzone, 2006-7) and sera collected for hemagglutination inhibition (HI) assay titers. Response to vaccination was defined as ≥ 1:40 titer ratio or a 4 fold increase in HI titer at 3 months post vaccination, against any of the 3 strains. Chi-square tests were performed to compare serological response between the groups with lowest and highest quartiles of baseline 25 (OH) vitamin D (D) level. Logistic regression model was used using other covariates such as age, gender, cancer type, and chemotherapy (CT) as controls.
[h=4]RESULTS:[/h] 85 patients with colorectal, 35 with prostate, 1 with anal and 1 with gastric adenocarcinoma participated in the study. Median age was 62 years (range: 24-87 years), 85 (70%) were males. Overall serological response was 59%. Median baseline D level was 42.9 ng/mL (range: 4.0-92.8 ng/mL); lowest and highest quartiles were 26.9 and 53.4 ng/mL. There was no association between serological response and baseline D level (p=0.42) or the lowest and highest quartiles of D level (p=0.6). The odds of response did not vary by sex (p=0.95). CRC patients (OR-0.051; 95% CI-0.013 to 0.209; p<0.0001) were less likely to respond. Few patients (n=20; 16%) were D deficient (<20ng/mL), 43 had D < 32ng/mL .70 patients (54.7%) were on vitamin D supplements. Among those in whom the dose of supplement was known (46),the median daily vitamin D supplement dose was 2000 IU (800-9000 IU).There was no association between serological response and dose (p=0.09). There was no difference in the response rates among patients on D supplement 44/70 (62.9%) versus those not on any D supplement 28/52 (53.8%)(p=0.32).
[h=4]CONCLUSIONS:[/h] Vitamin D status, in a population in which vitamin D supplementation was commonly used, did not affect serological response to influenza vaccine. No significant financial relationships to disclose.
PMID: 27961109
[PubMed - in process]
[h=1]Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients.[/h] Chadha MK[SUP]1[/SUP], Fakih MG[SUP]1[/SUP], Tian L[SUP]1[/SUP], Mashtare T[SUP]1[/SUP], Nesline M[SUP]1[/SUP], Davis W[SUP]1[/SUP], Silliman C[SUP]1[/SUP], Trump DL[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] e20575 Background: Increasing epidemiologic data suggest association of vitamin D deficiency with influenza epidemic. Vitamin D acts as an immune modulator and stimulates the expression of protective anti-microbial peptides. We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to flu vaccine in cancer patients.
[h=4]METHODS:[/h] Cancer patients at Roswell Park Cancer Institute were offered trivalent (H1N1, H3N2, B/Malaysia) Flu vaccine (Fluzone, 2006-7) and sera collected for hemagglutination inhibition (HI) assay titers. Response to vaccination was defined as ≥ 1:40 titer ratio or a 4 fold increase in HI titer at 3 months post vaccination, against any of the 3 strains. Chi-square tests were performed to compare serological response between the groups with lowest and highest quartiles of baseline 25 (OH) vitamin D (D) level. Logistic regression model was used using other covariates such as age, gender, cancer type, and chemotherapy (CT) as controls.
[h=4]RESULTS:[/h] 85 patients with colorectal, 35 with prostate, 1 with anal and 1 with gastric adenocarcinoma participated in the study. Median age was 62 years (range: 24-87 years), 85 (70%) were males. Overall serological response was 59%. Median baseline D level was 42.9 ng/mL (range: 4.0-92.8 ng/mL); lowest and highest quartiles were 26.9 and 53.4 ng/mL. There was no association between serological response and baseline D level (p=0.42) or the lowest and highest quartiles of D level (p=0.6). The odds of response did not vary by sex (p=0.95). CRC patients (OR-0.051; 95% CI-0.013 to 0.209; p<0.0001) were less likely to respond. Few patients (n=20; 16%) were D deficient (<20ng/mL), 43 had D < 32ng/mL .70 patients (54.7%) were on vitamin D supplements. Among those in whom the dose of supplement was known (46),the median daily vitamin D supplement dose was 2000 IU (800-9000 IU).There was no association between serological response and dose (p=0.09). There was no difference in the response rates among patients on D supplement 44/70 (62.9%) versus those not on any D supplement 28/52 (53.8%)(p=0.32).
[h=4]CONCLUSIONS:[/h] Vitamin D status, in a population in which vitamin D supplementation was commonly used, did not affect serological response to influenza vaccine. No significant financial relationships to disclose.
PMID: 27961109
[PubMed - in process]